Qualigen Therapeutics (NASDAQ: QLGN) Reveals New Executive and Board Appointments Along with Auditor Change

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: Oct 06 2025

0mins

Source: Newsfilter

Leadership Changes: Qualigen Therapeutics appointed Jerry Wang as Co-CEO and Koti Meka as CFO, both bringing extensive experience from Faraday Future, to enhance the company's executive team and financial transparency.
Board Expansion: The Board of Directors welcomed three new members and made several committee appointments, while also noting the amicable resignations of three previous board members, indicating a strategic shift in governance.
Auditor Transition: Qualigen engaged Macias Gini & O'Connell LLP as its new independent auditor after the resignation of WhitumSmith+Brown, marking a change in oversight for the company's financial reporting.
Company Focus: Qualigen Therapeutics, a biotechnology firm, is dedicated to developing oncology and immunology therapeutics while exploring crypto and web3 initiatives to drive global growth.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for NVDA?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy NVDA?

Get Started Free